The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

Introduction Epidermal growth factor receptor (EGFR) mutation T790M accounts for
approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Because …

BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …

Lung cancer is the leading cause of cancer-related death in the United States. Long
noncoding RNAs (lncRNA) are a class of regulatory molecules whose role in lung …

First-generation reversible EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed
our understanding of advanced non-small-cell lung cancer biology and behavior. The …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have demonstrated long survival
for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and …

Background A subset of patients with non‐small cell lung cancer (NSCLC) fosters mixed
responses (MRs) to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors …

Background Efficacies of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor
(TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung cancer …

Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …

The SARI (suppressor of AP-1, regulated by IFN) gene, which is also called BATF2, is
associated with the risk of several kinds of cancer, and loss of SARI expression is frequently …